<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/251857-a-lubricant-composition by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:41:20 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 251857:A LUBRICANT COMPOSITION</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A LUBRICANT COMPOSITION</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A lubricant composition for human vaginal delivery, the composition comprising: a polyacrylic acid, a water-soluble thickener, a humectant, optionally water, and optionally at least one active pharmaceutical ingredient, wherein component (a) is present in a proportion by weight of 0.1 -15% component (b) is present in a proportion by weight of 0.1 - 30%, and component (c) is present in a proportion by weight of 0.1-30%, based on the total weight of the composition.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Novel composition for easing human childbirth<br>
Description<br>
The present invention relates to a composition having a<br>
lubricant effect for use in particular in human vaginal<br>
delivery.<br>
Vaginal delivery of a child is a complex process and is<br>
determined by three substantial factors: the item to be<br>
delivered (fetus, amnion, placenta), the birth canal<br>
(consisting of a bony portion and a soft-tissue tube)<br>
and the delivery forces. Various delivery forces which<br>
promote or inhibit the vaginal delivery of a human<br>
fetus are known from the scientific specialist<br>
literature. Delivery-promoting forces are in this<br>
connection the labor contractions and the force of<br>
gravity, while delivery-inhibiting forces are the<br>
stretching force of the mouth of the womb and of the<br>
birth canal. Delivery of a human child is divided into<br>
3 phases: the dilation period, the expulsion period and<br>
the placental period. The normal duration of delivery<br>
in primiparas averages 12 hours, and in multiparas<br>
averages 8 hours. The reason for the shorter average<br>
duration of delivery in multiparas compared with<br>
primiparas is the reduced stretching force of the birth<br>
canal, because in multiparas the soft-tissue tube<br>
[inner soft-tissue duct (uterine segment - cervical<br>
canal - attached soft-tissue duct (vagina and vulva)]<br>
is thinned by the preceding vaginal deliveries. The<br>
prevailing doctrine relating to the mechanics of<br>
delivery in humans is accordingly that the stretching<br>
force of the birth canal (the force necessary to open,<br>
to stretch and to thin the birth canal) is to be<br>
regarded as a substantial force impeding delivery<br><br>
(Dudenhausen, Schneider, Frauenheilkunde und<br>
Geburtshilfe, Verlag De Gruyter (1994), pages 113 to<br>
121) .<br>
In veterinary medicine, the mechanical significance for<br>
delivery of the frictional force between item to be<br>
delivered and birth canal has been known for decades.<br>
Lubrication of the birth canal to reduce the frictional<br>
force is a standard method in veterinary obstetrics<br>
(Richter, Gotze; Tiergeburtshilfe, 4th edition; Verlag<br>
Paul Parey; Rechtsfragen in der Tiergeburtshilfe, page<br>
614), and lubricants for this purpose are commercially<br>
available. Relatively large volumes of lubricants can<br>
be employed in animal delivery. This makes it possible<br>
to use liquid, aqueous compositions which serve as<br>
substitute for the lubricating amniotic fluid or the<br>
allantoic fluid in productive livestock. It is not<br>
possible to use such large volumes in human vaginal<br>
delivery for lack of practicability.<br>
A substantial difference between delivery in animals<br>
and delivery in humans is that the role of the amniotic<br>
fluid in human delivery at term has no significant<br>
relevance in relation to lubrication of the birth canal<br>
and may on the contrary increase the resulting<br>
frictional forces. Amniotic fluid has, as an aqueous<br>
substance, little lubricant effect per se in humans. At<br>
present, vaginal deliveries in humans are mostly<br>
performed only with a chepalic presentation, where the<br>
escape of amniotic fluid during delivery must be<br>
designated negligible owing to the sealing by the head.<br>
The vernix caseosa, the only lubricant substance with<br>
the item to be delivered, is mostly no longer present<br>
at the time of delivery and anyway has only little<br>
effectiveness on the head. The use of amniotic fluid or<br><br>
substitute amniotic fluid for lubricating the birth<br>
canal before or during a vaginal delivery in humans is<br>
therefore not an appropriate measure for reducing the<br>
frictional forces and for easing vaginal delivery in<br>
humans.<br>
US patent 3 814 797 discloses aqueous lubricant<br>
compositions based on (A) potassium metaphosphate,<br>
(B) alginic acid, carboxymethylcellulose, carboxy-<br>
methylstarch and salts thereof and (C) the sodium salt<br>
of a weak acid, for example sodium carbonate or sodium<br>
phosphates.<br>
US patent 3 971 848 discloses a lubricant composition<br>
for mucous membranes, which comprises a mixture of<br>
fucoidin and an alginate. The composition may where<br>
appropriate be mixed with carboxymethylcellulose,<br>
sodium polyacrylate, potassium sodium polyphosphate,<br>
polyethylene oxide or the like and be employed for<br>
easing delivery.<br>
US patent 4 267 168 discloses a liquid biocidal<br>
composition which can be employed as cleaner, as<br>
surface disinfectant or as vaginal lubricant. The<br>
composition comprises lauryl diethanolamide, propylene<br>
glycol, glycerol, sodium polypectate and silver ions.<br>
It has a pH in the range of 7.2-7.8.<br>
JP 46024256 discloses a lubricant composition which<br>
consists essentially of polyacrylate and can be<br>
employed as assisting uterine fluid in veterinary<br>
medicine.<br>
JP 45000153 and JP 4500012 disclose a	lubricant<br>
composition for assisting delivery in	veterinary<br>
medicine, which comprises a salt or an ester	of alginic<br>
acid and gum arabic.<br><br>
 JP 46034991 discloses a lubricant composition<br>
comprising polyethylene oxide powder in a liquid<br>
consisting of an organic solvent in a concentration of<br>
&gt;80%, hydroxypropylcellulose, sodium sulfate and a<br>
detergent. The composition can be used after dilution<br>
to facilitate the extraction of a fetus in veterinary<br>
medicine.<br>
PCT/EP03/00548 discloses the use of a physiologically<br>
acceptable organic substance for producing a<br>
composition containing no alkali metal salts of meta-<br>
phosphates for use as lubricant in vaginal deliveries<br>
by women. Numerous examples of suitable,<br>
physiologically acceptable organic substances are<br>
mentioned. This invention relates to reducing the<br>
recently recognized substantial force impeding<br>
delivery, namely the frictional force between item to<br>
be delivered and birth canal through the use of a<br>
lubricant in humans.<br>
The object on which the present invention was based was<br>
to provide a composition for easing human childbirth<br>
which is physiologically tolerated and exhibits both<br>
good adhesion properties and a lubricant effect.<br>
This object is achieved by a bioadhesive composition<br>
having a lubricant effect, comprising (a) a polyacrylic<br>
acid, (b) a water-soluble thickener and (c) a humectant<br>
and (d) where appropriate water.<br>
Component (a) of the composition of the invention is a<br>
polyacrylic acid which may be crosslinked or/and<br>
chemically modified, or a salt of such a polyacrylic<br>
acid or a mixture of a plurality of polyacrylic acids.<br>
The average molecular weight of the acrylic acid<br>
polymers is chosen so that they exhibit bioadhesive<br>
properties in the intended application. The molecular<br>
weight is normally in the region of at least 2000 D and<br>
preferably up to 500 000 D.<br><br>
Preferred polyacrylic acids are crosslinked acrylic<br>
acid polymers, e.g. acrylic acid homopolymers,<br>
copolymers or interpolymers or salts of such polymers,<br>
e.g. alkali metal or alkaline earth metal salts. These<br>
include for example carbomer homopolymers, i.e. high<br>
molecular weight polymers of acrylic acid which are<br>
crosslinked by polyalkenyl ethers of sugars or poly-<br>
alcohols, such as, for example, allylsucrose, allyl-<br>
pentaerythritol etc., e.g. Carbopol® 940 NF, 974P NF or<br>
980 NF.<br>
Also suitable are carbomer copolymers, i.e. high<br>
molecular weight copolymers of acrylic acid and C1-C24-<br>
alkyl methacrylates crosslinked by polyalkenyl ethers<br>
of sugars or polyalcohols, such as, for example,<br>
Carbopol® 1382, Carbopol® 1342 NF, Carbopol® ETD-2020,<br>
Pemulen® TR1 NF and Pemulen® TR2 NF. Likewise suitable<br>
are carbomer interpolymers, i.e. carbomer homopolymers<br>
or copolymers which comprise a heterologous polymer,<br>
e.g. a block copolymer of polyethylene glycol and a<br>
long-chain, e.g. C1-C24-alkyl acid ester, such as, for<br>
example, Carbopol® Ultrez 10, 2 0 or 21 or Carbopol®<br>
Ultrez 10 NF. Likewise suitable are polycarbophils,<br>
i.e. polyacrylic acids crosslinked by divinyl glycol,<br>
such as, for example, Noveon® AA-1 USP, or calcium<br>
polycarbophils, i.e. calcium salts of polyacrylic acid<br>
crosslinked with divinyl glycol, such as, for example,<br>
Noveon® CA-1 USP and CA-2 USP.<br>
The polyacrylic acid homopolymers normally have a COOH<br>
group content of 56-68%, whereas the polyacrylic acid<br>
copolymers have a COOH group content of 52-62%.<br>
The proportion by weight of component (a) in the total<br>
weight of the composition may be varied within wide<br>
limits, for example from 0.1-15%. Especially when the<br>
composition is in the form of a hydrous gel, the<br>
proportion by weight of component (a) is preferably<br><br>
0.1-10%, particularly preferably 0.2-1% and even more<br>
preferably 0.4-0.7%. The proportion by weight is most<br>
preferably 0.45-0.5%.<br>
Component (b) of the composition is a water-soluble<br>
thickener or a mixture of a plurality of thickeners.<br>
Preferred examples are cellulose derivatives,<br>
especially hydrophilically modified cellulose<br>
derivatives such as, for example, hydroxy-<br>
ethylcellulose, hydroxypropylcellulose, carboxymethyl-<br>
cellulose, or/and hydroxypropylmethylcellulose. Further<br>
preferred water-soluble thickeners are<br>
mucopolysaccharides, in particular hyaluronic acid.<br>
Component (b) is normally present in a proportion by<br>
weight of 0.1-30%, preferably of 1-10%, particularly<br>
preferably of 2.5-7.5% and most preferably of 4-6%<br>
based on the total weight of the composition.<br>
Component (c) of the composition is a humectant or a<br>
mixture of a plurality of humectants. Preferred<br>
examples are pharmaceutically acceptable polyalcohols<br>
such as, for example, propylene glycol, especially 1,2-<br>
propylene glycol, glycerol or/and polyethylene glycol,<br>
especially liquid polyethylene glycol.<br>
Component (c) is normally present in a proportion by<br>
weight of 0.1-30%, preferably of 10-30%, particularly<br>
preferably of 15-25% and most preferably of 18-22%<br>
based on the total weight of the composition.<br>
Component (d) which is optionally present in the<br>
composition is water. In hydrous compositions, the<br>
water is normally present in a proportion by weight of<br>
40-95%, preferably of 60-85%, particularly preferably<br>
of 70-80% and most preferably of 72-77% based on the<br>
total weight of the composition. However, it is also<br>
possible where appropriate for the composition to be<br>
present and to be used in a form which has a lower<br><br>
water content or is dry, e.g. as powder, or/and be<br>
diluted shortly before use.<br>
Besides the abovementioned components, the composition<br>
may comprise excipients such as, for example,<br>
surfactants, dispersants, further thickeners, reagents<br>
to establish a pH value, carriers, fillers, stabilizers<br>
or/and preservatives. However, the composition is<br>
preferably free of preservatives. It is further<br>
preferred for the composition to be free of alginic<br>
acid or alginates, because addition of these substances<br>
often leads to the formation of unwanted discolorations<br>
or precipitates. The composition is likewise preferably<br>
free of metaphosphates or/and heavy metal ions,<br>
especially silver ions. The composition preferably<br>
further comprises ethylenediaminetetraacetic acid<br>
(EDTA) or/and pharmaceutically acceptable salts<br>
thereof.<br>
However, the composition preferably comprises means for<br>
establishing a substantially isotonic osmolarity, for<br>
example salts such as, for instance, sodium chloride in<br>
a proportion by weight normally of 0.1-5%, preferably<br>
of 0.3-0.6%, particularly preferably of 0.45-0.55% and<br>
most preferably for instance of 0.49-0.50% based on the<br>
total weight of the composition.<br>
The composition of the invention is preferably a gel<br>
which beneficially has a substantially colorless and<br>
transparent appearance. In addition, the composition<br>
may also be in the form of solid dosage forms such as<br>
tablets, powders, pastes, suppositories, coated<br>
tablets, effervescent tablets or suspensions thereof,<br>
or else in the form of a foam. The pH of the<br>
composition is preferably adjusted to a range of 4-7,<br>
preferably of 5-6 and most preferably of 5.5-6 by<br>
adding suitable reagents, e.g. acids such as HC1 or<br>
bases such as NaOH. The pH is preferably determined in<br>
this connection by potentiometry on a gel diluted 1:9<br><br>
in a 1.0% KNO3 solution.<br>
The viscosity of the composition is preferably in the<br>
range of 1-40 Pa-s, particularly preferably in the<br>
range of 10-18 Pa-s. The viscosity is preferably<br>
determined in this connection using a rotational<br>
viscometer, speed series N, level 4, sensor SV DIN,<br>
time 60 s, 20 revolutions at 20°C. The viscosity can<br>
alternatively be determined using a Brookfield RVT<br>
viscometer with the spindle rotating at a speed of 0.05<br>
to 100 revolutions per minute.<br>
The conductivity of the composition is preferably in<br>
the range of 4-25 mS.cm-1, particularly preferably of 8-<br>
12 mS•cm-1, determined with a conductivity meter, e.g.<br>
the Konduktor 702 from Knick, as specified in DIN<br>
61326/A1/VDE 0843 part 20/A1.<br>
The composition beneficially has thixotropic or/and<br>
pseudoplastic properties, with the viscosity decreasing<br>
under the influence of increasing shear stress or/and<br>
shear rate. The composition moreover preferably has a<br>
high initial shear stress or/and a pseudoplastic<br>
behavior, i.e. the adhesion of the composition<br>
decreases under the influence of increasing shear load.<br>
The composition may be in sterile form, in which case<br>
for example a steam sterilization or/and a<br>
sterilization by irradiation, e.g. by gamma<br>
irradiation, is possible. However, the composition may<br>
likewise be employed in non-sterilized form or/and<br>
comprise preservatives or/and biocidal substances.<br>
The production of the composition preferably includes<br>
the following steps:<br>
(i) preparation of a first mixture of polyacrylic<br>
acid (a) and water (d) , where appropriate with<br>
adjustment of the toxicity, e.g. by adding<br>
NaCl, or/and of the pH, e.g. by adding a base<br><br>
such as NaOH, the first mixture preferably<br>
being in the form of a gel,<br>
(ii) preparation of a second mixture of a water-<br>
soluble thickener (b) , of a humectant (c) and<br>
water (d) , the second mixture preferably being<br>
in the form of a gel,<br>
(iii) combining the two mixtures,<br>
(iv) where appropriate homogenization and<br>
(v) where appropriate sterilization.<br>
The process or individual steps thereof can be varied<br>
depending on the pharmaceutical form intended for the<br>
composition, or on additives which are possibly<br>
present. Thus, for example, water or/and humectant can<br>
be at least partly removed or/and added during the<br>
process.<br>
The composition is preferably in the form of packaged<br>
dosage units in a volume of 5-500 ml, particularly<br>
preferably in packaged dosage units in a volume of 10-<br>
20 ml. The composition is moreover advantageously in a<br>
packaging, for example jars, syringes, e.g. disposable<br>
syringes, or tubes, or it can be used as vaginal<br>
suppository. A further possibility is to employ a<br>
vaginal applicator. When jars are used, the composition<br>
can be applied using the fingers or spatulas to the<br>
surface of the birth canal. Tubes or syringes are more<br>
expedient, it being possible to apply the composition<br>
from them to the surface of the birth canal by<br>
pressure. The size of the packaging can be chosen so<br>
that the amount of the composition is sufficient for a<br>
single application. The tubes or syringes can be<br>
provided with an extension which substantially<br>
corresponds to the length of the birth canal and to the<br>
end of which the orifice for emergence of the<br>
composition is attached. The orifice for emergence is<br>
expediently designed, for example as round aperture, so<br>
that the composition can be completely and<br>
substantially uniformly distributed on the surface of<br><br><br>
Use of the composition to be used according to the<br>
invention is simple and effective when the composition<br>
is applied before onset of regular labour contractions,<br>
in the dilation phase or/and in the expulsion phase.<br>
Application can take place one or more times.<br>
Application shortly before or during the dilation phase<br>
may have the advantage that the tissue in the birth<br>
canal is softened, additionally facilitating delivery.<br>
The composition can likewise also be employed to<br>
facilitate removal of the placenta.<br>
In a preferred embodiment, the composition may<br>
additionally comprise one or more active pharmaceutical<br>
ingredients which serve as medicaments for certain<br>
indications occurring during delivery, e.g. delivery-<br>
inhibiting or delivery-promoting agents, agents to<br>
alleviate pain or/and agents to prevent infections. The<br>
amount of active pharmaceutical ingredients can be for<br>
example 0.0001-50% by weight, preferably 0.01-10% by<br>
weight and particularly preferably 0.01-5% by weight,<br>
based on the total weight of the composition.<br>
Some examples of delivery-inducing substances are<br>
oxytocin, dinoprostone, sulprostone, misoprostol and<br>
hyaluronidase.<br>
Some examples of delivery-inhibiting substances are<br>
chondroitin sulfate, hexoprenaline, fenoterol,<br>
magnesium sulfate, atosiban, calcium antagonists and<br>
nitroglycerin.<br>
Some examples of analgesic substances are bupivacaine,<br>
Carbostesin, lidocaine, mepivacaine, Rapidocaine,<br>
Scandicaine, Solarcaine and Xylesin.<br>
Some examples of antiinfectious agents and biocidal<br>
substances are antibacterial or/and antimicrobial<br><br>
or/and antiviral substances, such as quaternary-<br>
ammonium compounds, chlorhexidine, povidone-iodine and<br>
iodine, and iodine-containing compounds.<br>
It is particularly advantageous to admix antiviral<br>
substances, e.g. to prevent the transmission of herpes<br>
or HIV from the mother to the child, e.g. nucleoside<br>
analogs, nucleosidic reverse transcriptase inhibitors,<br>
non-nucleosidic reverse transcriptase inhibitors and<br>
protease inhibitors.<br>
It is likewise particularly advantageous to admix anti-<br>
bacterial substances, e.g. to prevent transmission of<br>
streptococci, e.g. type B streptococci, from the mother<br>
to the child, e.g. chlorhexidine.<br>
It has also proved expedient to admix pulmonary<br>
surface-active substances (pulmonary surfactants), with<br>
which the respiratory activity of the neonate after<br>
delivery can be facilitated, e.g. colfosceril<br>
palmitate, Lucinactant, Beractant, phospholipida e<br>
pulmone suis, perfluorocarbons.<br>
The composition is particularly suitable as lubricant<br>
for easing human vaginal childbirth or/and for<br>
facilitating removal of the placenta. It can be applied<br>
before or/and after the start of regular labour<br>
contractions one or more times as required. Application<br>
preferably takes place in the birth canal including<br>
mouth of the womb. Intraamniotic application may<br>
likewise be expedient.<br>
It is possible by use of the composition for human<br>
childbirth to be considerably eased and even reduced in<br>
duration, especially in primiparas when the walls of<br>
the mouth of the womb or/and vagina (birth canal) are<br>
covered with the lubricant before or/and during<br>
delivery. It is possible thus possible for the friction<br>
between birth canal and item to be delivered to be<br><br>
greatly reduced both in the dilation period and in the<br>
expulsion period. It is additionally possible to reduce<br>
or preclude the risk of injuries (such as, for example,<br>
thinning of the attached soft tissue duct, pelvic floor<br>
damage, vaginal tears, perineal injuries, rectal<br>
injuries, uterine ruptures, blood loss) and for long-<br>
term damage such as, for example, urinary incontinence,<br>
fecal incontinence, sexual dysfunction and<br>
psychological disturbances, to be restricted or<br>
prevented. Moreover, the work of delivery can be<br>
reduced due to the low friction, possibly leading to an<br>
avoidance or reduction in vaginal surgical procedures<br>
or caesarean sections. Manual removal of the placenta<br>
can also be facilitated by the lubricant of the<br>
invention.<br>
It is preferable for the delivery gel to be removed<br>
from the package while maintaining sterile conditions<br>
before use. During the delivery process, the gel is<br>
then applied one or more times intermittently to the<br>
birth canal by using the hand or another aid until the<br>
child's head is delivered. The aim in this case is for<br>
the birth canal to be covered as completely as possible<br>
with the lubricant gel. After the child's head has been<br>
delivered, the gel on the child's face can be wiped off<br>
with a cloth and, where appropriate, suction can<br>
additionally be applied to the mouth-nose region.<br>
Complete delivery of the child ideally takes place with<br>
the aid of a cloth, so that the child does not slip out<br>
of the hands.<br>
After delivery of the child or/and after delivery of<br>
the placenta, the birth canal is rinsed with an aseptic<br>
aqueous solution, preferably with a mild aseptic<br>
aqueous salt solution, so that the lubricant gel is<br>
dissolved. This can take place during or independently<br>
of the management of injuries to the perineum or the<br>
birth canal. The lubricant gel can, where appropriate,<br>
additionally be employed for facilitating the delivery<br><br>
of the placenta or manual removal of the placenta. The<br>
procedure in the management of a breech presentation<br>
delivery is analogous with adaptations.<br>
The present invention is further explained by the<br>
following examples:<br>
Examples<br><br><br><br>
The products of the above examples are clear, almost<br>
odorless and almost colorless transparent viscous gels<br>
having the following properties:<br>
pH 5.5-6.0<br><br>
pH determination: The pH is determined by potentiometry<br>
using a suitable pH-meter. A 10% solution of the gel in<br><br>
a 1.0% KNO3 solution is used for the measurement.<br>
Viscosity determination: The viscosity is determined<br>
using a rotational viscometer (instrument and measuring<br>
parameters: speed series N/level 4/sensor SV<br>
DIN/time 60 s/20 revolutions/min). All measurements<br>
take place at 20°C.<br>
Density: The density is determined using a pycnometer<br>
or using another equally suitable instrument. The<br>
formula used for calculation is<br>
δ20°c = m • 0.99703 + 0.0012 (g/cm3)δ<br>
M = mass of the liquids to be investigated, weighed in<br>
air<br>
W = mass of the same volume of water, weighed in air<br>
Both volumes must be measured at 20°C.<br>
Conductivity: The conductivity is measured using a<br>
conductivity meter complying with DIN 61326A1/VDE 0843<br>
part 2 0/A1.<br>
B Production example<br>
Production of 10 kg for packaging in 1000 syringes each<br>
containing 10 g<br>
Firstly, 49.5 g of sodium chloride are completely<br>
dissolved in 500 g of water in a homogenizer (Tornado<br>
ET21) . Then 48.5 g of polyacrylic acid (Carbopolum®<br>
940) and 2000 g of water are added and mixed by<br>
stirring for 5 minutes. Subsequently, while stirring<br>
for 10 minutes, sufficient aqueous 10 percent NaOH is<br>
added to establish a pH between 5.5 and 5.6. The gel<br>
produced in this way (mixture 1) is stored at room<br>
temperature until processed.<br><br>
450 g of hydroxyethylcellulose (hydroxyethylcellulosum<br>
H 300 p) are added to 2000 g of 1,3-propylene glycol<br>
and suspended in a stirred container. 4952 g of water<br>
are introduced into a homogenizer, and the suspension<br>
is added and then mixed and homogenized for 10 minutes.<br>
The gel-like mixture (mixture 2) is stored overnight<br>
(12 hours). Mixture 1 produced first is added to this<br>
mixture 2 and homogenized for 5 minutes.<br>
The finished gel is slightly opaque and transparent and<br>
odorless and has a pH of from 5.5 to 6.0. The viscosity<br>
is 16 000 mPas (measured with a Haake rotational<br>
viscometer, model VT 500, speed series N, level 4,<br>
sensor SV DIN, time 60 s, 20 revolutions/min, at 20°C).<br>
The gel is transferred into a sterile dispensing<br>
system, and 1000 syringes are charged with 10 g of gel.<br>
The outlet of the syringe is closed with a cap,<br>
subsequently sealed in a film and then sterilized at<br>
121°C for 15 minutes to give the product ready for use.<br>
C Use Examples<br>
Example 1:<br>
Use of lubricant for easing the dilation and expulsion<br>
periods during childbirth in humans<br>
A lubricant gel was used as specified in the invention<br>
in a group of 8 primiparous women. For this purpose,<br>
not only was the lubricant gel used as customary for<br>
vaginal examination; instead, the birth canal was<br>
intermittently covered manually with the lubricant. The<br>
amount of lubricant gel necessary for this was 10 to 15<br>
times higher than on use for vaginal examination. It<br>
was possible to establish in this investigated group<br>
that the average duration of delivery was significantly<br>
shorter than the established normal values, and that<br>
vaginal delivery by the women was overall easier than<br>
in comparable primiparas without the use of a<br><br>
lubricant. Overall, the trauma of delivery was less for<br>
mother and child. In addition, it was unnecessary in<br>
this investigated group to perform any vaginal surgery<br>
to complete delivery, and no injuries to the birth<br>
canal, such as vaginal tears, were found.<br>
Example 2:<br>
Use of lubricant for facilitating removal of the<br>
placenta<br>
In a group of 5 patients with post-partum retention of<br>
the placenta, manual removal of the placenta was<br>
facilitated by applying a lubricant to the arm of the<br>
person assisting delivery and to the birth canal. It<br>
emerged from this that manual removal of the placenta<br>
could be performed more easily and quickly, and that<br>
the blood loss could be reduced thereby.<br>
Biocompatibility test<br>
Test procedure<br>
Based on the following references, a biocompatibility<br>
test was carried out on formulation example 2 of the<br>
invention:<br>
1.	"In Vitro Fertilization and Embryo Transfer" A<br>
Manual of Basic Techniques. Ed.: Wolf, Don P., New<br>
York &amp; London: Plenum Press, Chapter 5: Mouse<br>
Embryo Culture Bioassay, pages 57-76, 1988.<br>
2.	ISO 10993-12, 2002, Biological Evaluation of<br>
Medical Devices - Part 12: Sample Preparation and<br>
Reference Materials.<br>
3.	ISO/IEC 17025, 2005, General Requirements for the<br>
Competence of Testing and Calibration<br>
Laboratories.<br>
In this test, two-cell mouse embryos were introduced<br>
into microtiter plate wells which contained a negative<br><br>
control (minimal medium (MEM)), the extract or a<br>
positive control (latex tube) or an extract of<br>
formulation example 2. Each test was carried out in<br>
duplicate with 10 embryos in each case, the embryos<br>
being kept in an incubator at a temperature of 37 ± 1°C<br>
for 72 ± 2 hours.<br>
Results<br>
After exposure for 72 hours, no significant decrease in<br>
the number of viable mouse embryos was observed for the<br>
extract of formulation 2 of the invention compared with<br>
the negative control, while the positive control<br>
brought about a marked decrease in the number of viable<br>
mouse embryos. Taking account of these test results,<br>
formulation example 2 of the invention was categorized<br>
as non-embryotoxic.<br><br>
WE CLAIM:<br>
1.	A lubricant composition for human vaginal delivery, the composition comprising:<br>
(a)	a polyacrylic acid,<br>
(b)	a water-soluble thickener,<br>
(c)	a humectant,<br>
(d)	optionally water, and<br>
(e)	optionally at least one active pharmaceutical ingredient,<br>
wherein component (a) is present in a proportion by weight of 0.1 -15%<br>
component (b) is present in a proportion by weight of 0.1 - 30%, and component<br>
(c) is present in a proportion by weight of 0.1-30%, based on the total weight of<br>
the composition.<br>
2.	The composition as claimed in claim 1, wherein component (a) comprises a<br>
crosslinked or/and chemically modified polyacrylic acid.<br>
3.	The composition as claimed in claim 1 or 2, wherein component (b) comprises a<br>
cellulose derivative, preferably hydroxyethylcellulose, hydroxypropylcellulose,<br>
carboxymethylcellulose or/and hydroxypropylmethylcellulose, or/and a<br>
mucopolysaccharide, preferably hyaluronic acid.<br><br>
4.	The composition as claimed in any of claims 1 to 3, wherein component (c )<br>
comprises propylene glycol, glycerol or/and polyethylene glycol.<br>
5.	The composition as claimed in any of claims 1 to 4, wherein component (a) is<br>
present in a proportion by weight of 0.1-10%, based on the total weight of the<br>
composition.<br>
6.	The composition as claimed in any of claims 1 to 5, wherein component (b) is<br>
present in a proportion by weight of 1-10%, based on the total weight of the<br>
composition.<br>
7.	The composition as claimed in any of claims 1 to 6, wherein component (c ) is<br>
present in a proportion by weight of 10-30%, based on the total weight of the<br>
composition.<br>
8.	The composition as claimed in any of claims 1 to 7, wherein it has a pH in the<br>
range of 4-7, preferably of 5.5-6.<br>
9.	The composition as claimed in any of claims 1 to 8, wherein it is sterilized.<br>
10.	The composition as claimed in any of claims 1 to 9, wherein it is free of<br>
preservatives.<br><br>
11. The composition as claimed in any of claims 1 to 10, wherein it is in the form of a<br>
gel, a tablet, a powder, a paste, a suppository, a coated tablet, an effervescent<br>
table, a suspension or a foam.<br><br><br>
A lubricant composition for human vaginal delivery, the composition comprising: a<br>
polyacrylic acid, a water-soluble thickener, a humectant, optionally water, and optionally<br>
at least one active pharmaceutical ingredient, wherein component (a) is present in a<br>
proportion by weight of 0.1 -15% component (b) is present in a proportion by weight of<br>
0.1 - 30%, and component (c) is present in a proportion by weight of 0.1-30%, based on<br>
the total weight of the composition.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-correspondence others 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1wY3QgcmVxdWVzdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE4MTYta29sbnAtMjAwNy1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">01816-kolnp-2007-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgwNS0wOS0yMDExKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(05-09-2011)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgwNS0wOS0yMDExKS1BTUFOREVEIENMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(05-09-2011)-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgwNS0wOS0yMDExKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(05-09-2011)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgwNS0wOS0yMDExKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(05-09-2011)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgwNS0wOS0yMDExKS1GT1JNIDEucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(05-09-2011)-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgwNS0wOS0yMDExKS1GT1JNIDIucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(05-09-2011)-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgwNS0wOS0yMDExKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(05-09-2011)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgxMC0wMi0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(10-02-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LSgyNC0xMi0yMDEyKS1GT1JNLTI3LnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-(24-12-2012)-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUFCU1RSQUNULnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIDEuMi5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-CORRESPONDENCE 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LURFU0NSSVBUSU9OIChDT01QTEVURSkucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVCBSRVBMWSBSRUNJRVZFRC5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-EXAMINATION REPORT REPLY RECIEVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUZPUk0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1rb2xucC0yMDA3LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1816-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUZPUk0gMi5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUZPUk0gMjYucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-FORM 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LU9USEVSUy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-OTHERS-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LU9USEVSUy0xLjIucGRm" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-OTHERS-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgxNi1LT0xOUC0yMDA3LVRSQU5TTEFURUQgQ09QWSBPRiBQUklPUklUWSBET0NVTUVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">1816-KOLNP-2007-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="251856-precision-fluid-delivery-system.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="251858-glass-strands-capable-of-reinforcing-organic-and-or-inorganic-materials.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>251857</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1816/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>15/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>13-Apr-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>12-Apr-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>22-May-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>HCB HAPPY CHILD BIRTH HOLDING AG.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>DUFOURSTRASSE 5, CH-4052 BASEL</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SCHAUB, ANDREAS, F.</td>
											<td>SURENWEG 7, CH-6318 WALCHWIL</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 9/00,A61K 31/70</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP05/012058</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-11-10</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>10 2004 054 552.9</td>
									<td>2004-11-11</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/251857-a-lubricant-composition by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:41:21 GMT -->
</html>
